Story

ClearOne Stock Surges Over 90% on Shareholder Approval for Cortigent Merger

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20261 min read
ClearOne Stock Surges Over 90% on Shareholder Approval for Cortigent Merger
Text size
Background

Shares of ClearOne, Inc. (CLRO) surged more than 90% in pre-market trading Tuesday after the company secured a critical shareholder approval needed to advance its planned merger with Cortigent, Inc. The approval, detailed in a regulatory filing, clears a significant hurdle for the transaction and reinforces investor confidence in the deal's timeline.

Key Merger Milestone

In an after-hours filing on August 5, ClearOne disclosed that holders representing approximately 61.3% of its voting stock had provided written consent for the issuance of 12.5 million new common shares to Vivani Medical. This share issuance was a key condition required to close the merger.

The market reacted swiftly to the news, which significantly de-risks the transaction. The company's stock rallied to trade at $7.00 a share in pre-open activity, a jump of 90.2%.

Supporting Corporate Actions

Alongside the shareholder vote, ClearOne announced several other developments that underscore its commitment to completing the merger and its strategic transition. These actions include:

Sample IUX Markets – In-articleAd
  • Warrant Cancellation: The company canceled warrants previously held by First Finance to purchase 437,500 shares, a move intended to streamline its capital structure ahead of the merger's close.
  • Executive Agreement: A new employment agreement was secured for Chief Financial Officer Simon Brewer, which will become effective upon the completion of the deal.

Context and Strategic Pivot

The dramatic pre-market move in ClearOne's stock was entirely company-specific, occurring while broader market indexes like the S&P 500 and Dow Jones posted only modest gains. The merger with Cortigent, first announced in early July 2026, represents a strategic pivot for ClearOne from its legacy audio-visual communications business.

The combined company is set to operate as Cortigent Holdings, focusing on the high-growth neurostimulation and brain-computer interface sector. According to previous announcements, the transaction is targeted to close in the third quarter of 2026.

Read next

More on Stocks
Back to latest news

LATEST